Copaxone (glatiramer acetate) — the complete 2026 guide: how it works, GALA efficacy, pregnancy safety, and access in Serbia
Copaxone (glatiramer acetate) is the original and longest-used DMT for multiple sclerosis — in continuous use for over 30 years. Given as a self-administered subcutaneous injection (20 mg daily or 40 mg three times a week), it offers modest efficacy but exceptional safety: no PML, no blood monitoring, safe in pregnancy. A detailed guide: mechanism, GALA and GATE trials, injection-site reactions, lipoatrophy, generic glatiramer, and RFZO coverage in Serbia.
What is Copaxone
From my own experience, I know that topics like this need more nuance than a quick answer. Copaxone is the brand name for glatiramer acetate — a synthetic mixture of four amino acids (L-glutamic acid, L-lysine, L-alanine, L-tyrosine in a 1.4:3.4:4.2:1.0 ratio). Developed at the Weizmann Institute (Israel) in 1971 and brought to market by Teva. The FDA approved it in December 1996 — it was the second DMT ever approved for MS (after interferon beta-1b) and the first non-interferon ([FDA 1996](https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020622s089lbl.pdf); [EMA EPAR — Copaxone](https://www.ema.europa.eu/en/medicines)). With over 3 million patient-years of cumulative exposure, Copaxone is the longest-used and best-studied DMT in MS history.
How it works
Glatiramer acetate was designed to resemble myelin basic protein (MBP) — the main antigen driving the autoimmune attack in MS. Its mechanism is complex and still not fully understood, but several pathways are known ([Lalive PH et al. CNS Drugs 2011](https://link.springer.com/article/10.2165/11591110-000000000-00000)):
MHC-II competition — glatiramer binds MHC-II molecules on antigen-presenting cells and blocks presentation of real MBP fragments. Th1 → Th2 shift — induces glatiramer-specific CD4+ T cells that secrete anti-inflammatory cytokines (IL-4, IL-10, TGF-β) instead of pro-inflammatory ones (IFN-γ, TNF-α). Regulatory T cells (Tregs) — expands the number and function of Tregs that suppress autoreactive cells. Neuroprotection — increases the release of BDNF (brain-derived neurotrophic factor), which helps neuron survival and may promote remyelination.
Who it is approved for
- Relapsing-remitting MS (RRMS) in adults — as a first- or second-line therapy.
- Clinically isolated syndrome (CIS) — patients with a first demyelinating episode and MRI findings suggesting MS, to delay conversion to definite MS ([PreCISe study, Comi G et al. Lancet 2009](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61259-9/fulltext)).
- NOT approved for primary progressive (PPMS) or non-active secondary progressive MS.
What the pivotal trials showed
Pivotal trial (Johnson 1995)
A 2-year trial of 251 patients comparing Copaxone 20 mg daily with placebo ([Johnson KP et al. Neurology 1995](https://n.neurology.org/content/45/7/1268)):
- 29% reduction in annualized relapse rate (ARR 0.59 vs 0.84).
- Fewer patients with disability progression (21.6% vs 24.6%).
- Excellent safety profile — mostly local injection-site reactions.
GALA trial (2013)
A phase 3 trial of 1,404 patients comparing Copaxone 40 mg three times a week with placebo over 12 months ([Khan O et al. Ann Neurol 2013](https://onlinelibrary.wiley.com/doi/10.1002/ana.23938)):
- 34% reduction in annualized relapse rate (ARR 0.33 vs 0.50).
- 44% fewer T1 Gd+ MRI lesions.
- 44.8% fewer new T2 lesions.
GALA changed the dosing standard — from 7 injections a week to just 3, with the same efficacy and better tolerability.
GATE trial (2015)
A trial of 794 patients comparing generic glatiramer (Glatopa, Mylan/Sandoz) with original Copaxone and placebo ([Cohen J et al. JAMA Neurol 2015](https://jamanetwork.com/journals/jamaneurology/fullarticle/2424942)). Result: clinical and MRI equivalence — which led to FDA approval of the first generic glatiramer in 2015.
Real-world data
Long-term data from CLIMB (Brigham/Harvard) and the MSBase registry show that patients on Copaxone have lower cumulative relapse rates and slower disability progression over 10–15 years, especially when started early after diagnosis.
How it is given — dosing regimens
Copaxone is available in two regimens:
- 20 mg daily subcutaneous — the original 1996 regimen, rarely used today.
- 40 mg three times a week subcutaneous (e.g. Mon/Wed/Fri, ≥48 hours apart) — approved in 2014 based on GALA; today the standard for most patients.
Both doses deliver the same cumulative efficacy, but the 40 mg regimen halves the number of injections and reduces injection-site reactions.
Injection sites
The injection is given subcutaneously (not intramuscularly) in one of 7 zones: abdomen (left/right), thighs (left/right), upper buttocks (left/right), back of the arm. A strict rotation schedule is recommended — the same site should not be used more than once a week.
Equipment
- Sterile prefilled syringe (PFS) — 1 mL.
- Autoject 2 autoinjector — helps patients with tremor, pain, or needle phobia.
- Refrigerator (2–8 °C) for storage; warm to room temperature for 20 minutes before use.
Side effects and how to mitigate them
Injection-site reactions (60–70%)
Redness, swelling, pain, itching, induration (a firm lump) at the injection site. Usually resolves within 24 hours. Mitigation: site rotation, cold packs before and after, autoinjector.
Post-injection reaction (PIR, ~15%)
A systemic reaction occurring in ~15% of patients immediately after injection: flushing, palpitations, shortness of breath, chest pain, anxiety. Lasts 5–15 minutes and resolves spontaneously. It is not an allergy and does not require treatment interruption, but it can be alarming the first time it happens. It typically occurs once or twice over years of therapy, not every time.
Lipoatrophy (5–10%)
Permanent loss of subcutaneous fat at repeated injection sites — visible "dents" under the skin. More common in women. Not dangerous, but permanent. Prevention: strictly rotate all 7 zones, use short needles (29–30G), and proper deep technique.
Systemic side effects (rare)
- Lymphadenopathy (swollen lymph nodes).
- Headache, nausea, fatigue — in <5%.
- No hepatotoxicity, no haematological problems, no need for routine blood monitoring.
Safety — why Copaxone is "the safest DMT"
Copaxone is often the first-line DMT chosen for its exceptional safety:
No PML — unlike Tysabri, fingolimod, or anti-CD20 drugs. No immunosuppression — it does not alter blood counts or increase the risk of infections or cancers. No vaccine interactions — patients can receive all live and inactivated vaccines without interrupting therapy. No lab monitoring required — no routine liver, blood count, or JCV antibody testing needed. 30+ years of experience — the longest safety record of any MS therapy.
Pregnancy and breastfeeding
Copaxone is one of the few DMTs that can be continued during pregnancy. The large glatiramer molecule (4,700–11,000 Da) does not cross the placenta to a meaningful degree ([EAN guidelines 2022, Dobson R et al. Eur J Neurol 2023](https://onlinelibrary.wiley.com/doi/10.1111/ene.15462)).
Pregnancy registries with more than 8,000 pregnancies show no increase in malformations, preterm birth, or low birth weight. Recommendation: if disease control is needed, therapy can be continued throughout pregnancy. Breastfeeding: glatiramer is not excreted into breast milk in clinically significant amounts — breastfeeding is safe.
This makes Copaxone an ideal choice for young women planning a pregnancy or with mildly-to-moderately active MS.
Generic glatiramer — Glatopa and others
Since 2015, generic glatirameres have become available:
- Glatopa (Mylan/Sandoz) — the first FDA-approved generic, clinically equivalent to Copaxone (GATE trial).
- Glatiramer Acetate Injection (Mylan) — 40 mg formulation approved in 2017.
- Numerous European generics available from 2016 onward.
Generics are 30–50% cheaper and therapeutically equivalent — which has substantially reduced the cost of DMT therapy globally.
Copaxone in Serbia — RFZO and practical steps
Copaxone (Teva) and generic glatiramer are available in Serbia via the RFZO Lista C and 100% reimbursed through mandatory health insurance for patients with relapsing-remitting MS who meet the criteria ([RFZO drug list](https://rfzo.rs/index.php/davalciusluga/lekovi-info/lekovi-lista)).
Eligibility criteria
- Confirmed diagnosis of RRMS by McDonald 2017 criteria.
- EDSS ≤ 5.5.
- At least 2 relapses in the last 2 years or 1 relapse + MRI activity.
- Assessment at an MS centre (KCS Belgrade, KC Niš, KC Novi Sad, KC Kragujevac, VMA).
Practical steps
1. Appointment with the MS-centre neurologist with all prior documentation and MRI scans.
2. The MS-centre commission decides on therapy and submits a request to RFZO.
3. RFZO approval — usually within 2–4 weeks.
4. Monthly drug pick-up at the MS-centre pharmacy or a designated pharmacy.
5. Self-injection training by a nurse (1 hour).
6. Follow-up with the neurologist every 6 months.
Who is Copaxone suitable for
- Patients with mildly-to-moderately active RRMS who want a safe first-line therapy.
- Young women planning pregnancy or breastfeeding.
- Patients at low risk of progression and with few MRI lesions.
- Those who cannot or do not want regular blood tests or infusions.
- Patients who have had PML, serious infections or have contraindications to anti-CD20 drugs.
Who is it NOT suitable for
- Highly active RRMS with frequent relapses and many Gd+ lesions — Ocrevus, Kesimpta, Tysabri or Mavenclad are better.
- Progressive MS without relapses — Copaxone has no proven efficacy.
- Patients with severe needle phobia unable to use an autoinjector.
- Pre-existing severe lipoatrophy affecting quality of life.
Practical self-injection tips
- Temperature: take the syringe out of the fridge 20 minutes before — a cold injection hurts more.
- Rotation: keep a journal of injection sites; free apps exist (CopaxoneApp).
- Technique: clean skin, pinch fatty tissue, inject at 90° (autoinjector) or 45° (manual).
- After injection: a cold pack for 1–2 minutes reduces redness and pain.
- Needle anxiety: use the Autoject 2 — the needle is hidden.
- PIR (post-injection reaction): if it happens, sit down and breathe calmly — it passes in 10–15 minutes. Tell your neurologist at the next visit.
In 2026, Copaxone (glatiramer acetate) is still a cornerstone of MS therapy for patients who prioritise safety. It does not have the high efficacy of anti-CD20 drugs or natalizumab, but it has the longest and best safety record of any DMT: no PML, no blood monitoring, safe in pregnancy and breastfeeding, compatible with every vaccine. It is ideal for young women planning a family, patients with mildly active RRMS, and anyone with a history of serious infections. In Serbia it is 100% reimbursed on RFZO Lista C as a first-line therapy. The combination of long experience, safety, and accessibility makes Copaxone a proven, "gentle" option in an era of highly effective but riskier DMTs.
Sources
Johnson KP et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting MS. Neurology 1995: https://n.neurology.org/content/45/7/1268. Khan O et al. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis (GALA). Ann Neurol 2013: https://onlinelibrary.wiley.com/doi/10.1002/ana.23938. Cohen J et al. Equivalence of generic glatiramer acetate in multiple sclerosis (GATE). JAMA Neurol 2015: https://jamanetwork.com/journals/jamaneurology/fullarticle/2424942. Comi G et al. Effect of glatiramer acetate on conversion to clinically definite MS (PreCISe). Lancet 2009: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61259-9/fulltext. Lalive PH et al. Glatiramer acetate in the treatment of multiple sclerosis. CNS Drugs 2011. Dobson R et al. EAN consensus on pregnancy in MS. Eur J Neurol 2023: https://onlinelibrary.wiley.com/doi/10.1111/ene.15462. EMA EPAR — Copaxone: https://www.ema.europa.eu/en/medicines. RFZO drug list: https://rfzo.rs/index.php/davalciusluga/lekovi-info/lekovi-lista. This article is educational, does not constitute medical advice, and must not be used as the basis for changing therapy without consulting your MS-centre neurologist.